Massive claims study aims to validate heart failure drug findings
NCT ID NCT07599345
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study uses healthcare claims data from over 23,000 people with heart failure and type 2 diabetes to see if the drug empagliflozin works as well in everyday practice as it did in a major clinical trial. Researchers compare empagliflozin to another diabetes drug, sitagliptin, looking at deaths and hospitalizations. The goal is to learn how to use real-world data confidently for future medical decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.